BCL2 and neoplasm: Synergetic effects of CM03 and SAHA have yet to be demonstrated in tumor models in vivo but synergy between quadruplex ligands and other chemotherapeutic agents has been well documented, for example between BRACO19 and paclitaxel [48], cis-platinum with the BRACO19 derivative AS1410 [49], RHPS4 with taxol [50], and the BCL-2 inhibitor Navitoclax with the quadruplex-binding compound GQC-05 [51].